| pubmed-article:11082120 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0079281 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0458827 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0079284 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0015376 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0332257 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0178987 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:11082120 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:11082120 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:11082120 | pubmed:dateCreated | 2001-2-2 | lld:pubmed |
| pubmed-article:11082120 | pubmed:abstractText | 1. The effect of the novel ET(A) receptor antagonist LBL 031 and other selective and mixed endothelin receptor antagonists on endothelin-1 (ET-1)-induced and lipopolysaccharide (LPS)-induced microvascular leakage was assessed in rat airways. 2. Intravenously administered ET-1 (1 nmole kg(-1)) or LPS (30 mg kg(-1)) caused a significant increase in microvascular leakage in rat airways when compared to vehicle treated animals. 3. Pre-treatment with the selective ET(A) receptor antagonists, LBL 031 or PD 156707, or the mixed ET(A/B) receptor antagonist, bosentan (each at 30 mg kg(-1)), reduced ET-1-induced leakage to baseline levels. ET-1-induced leakage was not reduced by pre-treatment with the ET(B) selective antagonist BQ 788 (3 mg kg(-1)). 4. Pre-treatment with the selective ET(A) receptor antagonist, LBL 031 (0.1 mg kg(-1)) or PD 156707 (10 mg kg(-1)), or the mixed ET(A/B) receptor antagonist, bosentan (30 mg kg(-1)), reduced LPS-induced leakage by 54, 48 and 59% respectively. LPS-induced leakage was not affected by pre-treatment with the ET(B) selective antagonist BQ 788 (3 mg kg(-1)). 5. The data suggests that ET-1-induced microvascular leakage in the rat airway is ET(A) receptor mediated and that part of the increase induced by LPS may be due to the actions of ET-1. Therefore, a potent ET(A) receptor selective antagonist, such as LBL 031, may provide a suitable treatment for inflammatory diseases of the airways, especially those involving LPS and having an exudative phase, such as the septic shock-induced adult respiratory distress syndrome. | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11082120 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11082120 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11082120 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11082120 | pubmed:issn | 0007-1188 | lld:pubmed |
| pubmed-article:11082120 | pubmed:author | pubmed-author:BelvisiM GMG | lld:pubmed |
| pubmed-article:11082120 | pubmed:author | pubmed-author:WebberS ESE | lld:pubmed |
| pubmed-article:11082120 | pubmed:author | pubmed-author:HuntT WTW | lld:pubmed |
| pubmed-article:11082120 | pubmed:author | pubmed-author:FosterM LML | lld:pubmed |
| pubmed-article:11082120 | pubmed:author | pubmed-author:BirrellM AMA | lld:pubmed |
| pubmed-article:11082120 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11082120 | pubmed:volume | 131 | lld:pubmed |
| pubmed-article:11082120 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11082120 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11082120 | pubmed:pagination | 1129-34 | lld:pubmed |
| pubmed-article:11082120 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:meshHeading | pubmed-meshheading:11082120... | lld:pubmed |
| pubmed-article:11082120 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11082120 | pubmed:articleTitle | Effect of endothelin antagonists, including the novel ET(A) receptor antagonist LBL 031, on endothelin-1 and lipopolysaccharide-induced microvascular leakage in rat airways. | lld:pubmed |
| pubmed-article:11082120 | pubmed:affiliation | Department of Pharmacology, Research & Development, Aventis Pharma, Rainham Road South, Dagenham, Essex RM10 7XS. | lld:pubmed |
| pubmed-article:11082120 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11082120 | lld:pubmed |
